Botulinum Toxin Injection Into Epicardial Fat Pads to Prevent Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Launched by MESHALKIN RESEARCH INSTITUTE OF PATHOLOGY OF CIRCULATION · Nov 27, 2015
Trial Information
Current as of May 30, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key inclusion Criteria:
- • Indication for cardiac surgery (e.g. coronary artery bypass grafting, valve repair/replacement) according to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines for cardiac surgery
- Key exclusion Criteria:
- • Planned maze procedure or pulmonary vein isolation
About Meshalkin Research Institute Of Pathology Of Circulation
The Meshalkin Research Institute of Pathology of Circulation is a leading clinical research organization dedicated to advancing cardiovascular health through innovative research and development. Renowned for its commitment to scientific excellence, the institute specializes in studying the pathophysiology of circulatory diseases and developing novel therapeutic approaches. With a multidisciplinary team of experts, state-of-the-art facilities, and a robust infrastructure for clinical trials, the institute plays a pivotal role in translating research findings into practical solutions that enhance patient outcomes and contribute to the global understanding of cardiovascular conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Novosibirsk, , Russian Federation
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials